Efficacy and safety of cyclin‐dependent kinase 4/6 inhibitor in patients with advanced breast cancer: A real‐world experience
Abstract Background Cyclin‐dependent kinases 4 and 6 inhibitors (CDK4/6i) have been shown to improve progression‐free survival (PFS) in patients with metastatic breast cancer (MBC) in randomized control trials. This study aimed to evaluate the efficacy and safety of CDK4/6i in patients with advanced...
Збережено в:
| Автори: | , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Wiley
2023-10-01
|
| Серія: | Thoracic Cancer |
| Предмети: | |
| Онлайн доступ: | https://doi.org/10.1111/1759-7714.15090 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|